Watson Pharmaceuticals Inc. said it acquired the U.S. rights to a generic version of Celgene Corp.'s billion-selling cancer drug Revlimid.
Pfizer Inc. may be the world's biggest drugmaker, but new CEO Ian Read is taking charge at a trying time for the company, and he will have to deal with a declining share price, repeated failures of potential new products and expirations of patents on key drugs.
The Global Fund to Fight AIDS, Tuberculosis and Malaria said that $4 million meant to fight disease in Mali has been misappropriated, prompting them to halt three grants.
A new report from British scientists suggests that long-term, low-dose aspirin use may modestly reduce the risk of dying of certain cancers, though experts warn the study isn't strong enough to recommend healthy people start taking a pill that can cause bleeding and other problems.
NovaBay Pharmaceuticals, Inc. and Galderma announce the expansion of their multi-year collaboration agreement to include impetigo.
A clinical trial investigator said more occurrences of observed secondary malignancies have been found in patients who received a maintenance dose of the myeloma treatment, Revlimid, compared to those who received a placebo.
Researchers from the A*STAR Institute of Micro-electronics Bioelectronics program in Singapore are developing a cost-effective and more rapid way to help physicians assess the effectiveness of treatments to cancer patients.
A team of scientists has collaborated with Pfizer Inc. to develop a test to select which patients with ovarian cancer will benefit from drugs called PARP inhibitors, according to research.
S*BIO Pte Ltd announced that data from Phase 1/2 studies for its novel JAK2 inhibitor SB1518 indicates clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis and enlarged spleens.
Human Genome Sciences Inc. and GlaxoSmithKline PLC said that the Food and Drug Administration wants three more months before making a decision on their lupus drug candidate Benlysta, delaying the agency's decision until around March 10.
Ethel Johnson couldn't get her prescription for pain medication filled fast enough. The 60-year-old Buffalo woman was hurting - but investigators say that wasn't the reason for the rush.
Pfizer Inc. abruptly replaced its CEO and chairman, saying Jeffrey B. Kindler was retiring after 4 1/2 years leading the world's biggest drugmaker to "recharge."
Over the last decade, electronic data capture has fundamentally transformed the way biopharmaceutical companies and regulatory agencies view clinical development activities.
The diversity of ion channels, their involvement in a broad spectrum of physiologic mechanisms, and their accessibility on the cell surface make them attractive drug targets.
As the life sciences migrate towards a paperless work flow, electronic notebooks are becoming a popular option to manage data, aid in IP searches, and enable collaboration.